Show simple item record

dc.contributor.authorThoonen, Robrecht
dc.contributor.authorSips, Patrick
dc.contributor.authorBloch, Kenneth Daniel
dc.contributor.authorBuys, Emmanuel
dc.date.accessioned2015-03-18T18:17:24Z
dc.date.issued2012
dc.identifier.citationThoonen, Robrecht, Patrick Y. Sips, Kenneth D. Bloch, and Emmanuel S. Buys. 2012. “Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling.” Curr Hypertens Rep 15 (1) (December 12): 47–58. doi:10.1007/s11906-012-0320-5.en_US
dc.identifier.issn1522-6417en_US
dc.identifier.issn1534-3111en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:14229236
dc.description.abstractThe nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling system is a well-characterized modulator of cardiovascular function, in general, and blood pressure, in particular. The availability of mice mutant for key enzymes in the NO-cGMP signaling system facilitated the identification of interactions with other blood pressure modifying pathways (e.g. the renin-angiotensin-aldosterone system) and of gender-specific effects of impaired NO-cGMP signaling. In addition, recent genome-wide association studies identified blood pressure-modifying genetic variants in genes that modulate NO and cGMP levels. Together, these findings have advanced our understanding of how NO-cGMP signaling regulates blood pressure. In this review, we will summarize the results obtained in mice with disrupted NO-cGMP signaling and highlight the relevance of this pathway as a potential therapeutic target for the treatment of hypertension.en_US
dc.language.isoen_USen_US
dc.publisherSpringer Science + Business Mediaen_US
dc.relation.isversionofdoi:10.1007/s11906-012-0320-5en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544991/en_US
dash.licenseLAA
dc.subjectCyclic guanosine monophosphateen_US
dc.subjectBlood pressureen_US
dc.subjectHypertensionen_US
dc.subjectCardiovascular functionen_US
dc.subjectSoluble guanylate cyclaseen_US
dc.subjectNitric oxideen_US
dc.subjectMutant miceen_US
dc.subjectGenetic variantsen_US
dc.subjectRenin-angiotensin-aldosterone signalingen_US
dc.subjectGenderen_US
dc.subjectS-nitrosylationen_US
dc.subjectTherapeuticsen_US
dc.titlePathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signalingen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalCurrent Hypertension Reportsen_US
dash.depositing.authorBuys, Emmanuel
dc.date.available2015-03-18T18:17:24Z
dc.identifier.doi10.1007/s11906-012-0320-5*
dash.contributor.affiliatedThoonen, Robrecht
dash.contributor.affiliatedSips, Patrick
dash.contributor.affiliatedBuys, Emmanuel
dash.contributor.affiliatedBloch, Kenneth


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record